Original Data

Quality of Life and Patient-Perceived Difficulties in the Treatment of Type 2 Diabetes

Orly Tamir¹, Julio Wainstein^2,3, Itamar Raz⁴, Joshua Shemer^1,3,5, Anthony Heymann^3,6

Manuscript submitted April 4, 2012.

Keywords: type 2 diabetes, patient perception, quality of life, oral hypoglycemic agent, insulin

Abstract

BACKGROUND: Clinical evidence points to patient-perceived difficulties and compliance problems in implementing early insulin therapy. Therefore, individual treatment aims are necessary to optimize diabetes therapy, as currently acknowledged by the new ADA/EASD guidelines. Better characterization of patient-perceived difficulties in the implementation of early insulin treatment may contribute to improved compliance and optimal tailoring of treatment regimens for the individual patient. OBJECTIVES: To assess differences in quality of life (QoL) and patient-perceived difficulties in health care with every addition of oral hypoglycemic agents (OHAs) and insulin therapy. METHODS: The analysis was conducted on a cross-sectional sample of 714 diabetic patients treated with OHAs or with insulin once or twice daily. Differences in diabetes-specific QoL, overall QoL, and perception of difficulties associated with specific diabetes treatment attributes were evaluated using trend analysis and comparisons between groups. The contribution of each diabetes treatment attribute to QoL measures and glycemic control was also assessed. RESULTS: No significant differences were found in QoL measures among patients treated exclusively with OHAs when these patients were assessed by the number of oral agents, irrespective of the degree of glycemic control. Better controlled patients treated with 2 OHAs, compared with poorly controlled patients treated with a single OHA, had a lower perception of difficulties associated with diabetes treatment attributes. Poorly controlled patients treated with 2 OHAs and better controlled patients treated with 3 OHAs had similar QoL and perceived difficulties with care. However, the insulin-based alternative was consistently associated with a significantly higher perception of pain and lower overall QoL when compared with the oral regimens. Multivariate models accounted for 52% and 32% of the variance in QoL measures. CONCLUSIONS: From the patients’ perspective, oral therapy is the preferred strategy for attaining the treatment goals since the addition of OHAs was not associated with lower QoL or patient-perceived difficulties with care. If early insulin treatment is considered, physicians should address specific diabetes treatment characteristics, mainly the issue of pain, to promote improved QoL and disease control.

Fulltext: HTML , PDF (260KB)

This article has been cited by other articles:

	Insulin-associated weight gain in obese type 2 diabetes mellitus patients - what can be done? Brown A, Guess N, Dornhorst A, Taheri S, Frost G Diabetes Obes Metab 2017. In press
	The importance of medication adherence Martinez Dominguez GI, Martinez Sanchez LM, Vargas Grisales N, Lopera Valle JS Rev Venez Endocrinol Metab 2016. 14(2):107-116
	Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study Forst T, Koch C, Dworak M Curr Med Res Opin 2015. 31(6):1079-1084
	Relationship of treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus: Findings from a cross-sectional study Zyouda SH, et al. J Clin Transl Endocrinol 2015. 2(2):66-71
	Diabetes and quality of life: a Ugandan perspective Nyanzi R, Wamala R, Atuhaire LK J Diabetes Res 2014. 2014:402012
	Increase in postoperative insulin requirements does not lead to decreased quality of life after total pancreatectomy with islet cell autotransplantation for chronic pancreatitis Dorlon M, Owczarski S, Wang H, Adams D, Morgan K Am Surg 2013. 79(7):676-680